For Research Use Only in the United States. Not for use in diagnostic procedures.

The MicroVue C3a Plus EIA measures the amount of C3a-desArg present in human plasma and serum.

C3a is generated during the activation of the complement system via the classical or alternative pathway. The anaphylatoxin C3a itself is very short lived and in serum is cleaved rapidly to the more stable C3a-desArg. Therefore, quantitation of C3a-desArg allows reliable conclusions about the level of complement activation in a test sample. For convenience, we refer to both forms as C3a. The MicroVue C3a Plus EIA measures concentrations of C3a in human plasma and sera. It uses a proprietary monoclonal antibody to a neo-epitope on C3a to capture C3a in the solid phase. The trapped C3a is subsequently detected by HRP-labeled antibodies to C3a antigens. This test provides a rapid, non-radioactive method for assessing C3a levels. It is designed for investigations into the role and or status of complement activation in numerous research and clinical settings. An EIA for the detection of C3a (C3a-desArg) in human serum and plasma.